drug
WVE-007
Phase 2updated 6mo agoby $WVE Wave Life Sciences Ltd.
Phase 2community read0 votes
indications
indications
Obesity
all catalysts(0)
nothing on the calendar yet
Trials studying WVE-007
News(4)
- Summit’s rejection, Isomorphic’s record $5B raise, obesity and Alzheimer’s in the spotlightThe FDA declined to approve Summit Therapeutics’ Akeso-partnered ivonescimab, putting other PD-1/VEGF drug developers on notice; Isomorphic bagged a $5 billion series C, the largest in biotech hist…biospace · 16h ago
- ObesityWeek 2026: Wave outlines case for body composition–based trial designAcross three cohorts in Wave Life Sciences’ mid-stage trial of WVE-007, higher baseline body mass index and excessive body fat have been associated with a more pronounced effect, Rodman & Renshaw s…biospace · 2d ago
- Biopharma pushes beyond GLP-1s, weight loss at ObesityWeek 2026ObesityWeek 2026, which kicks off on Saturday, will spotlight presentations on the ascendant amylin pathway, as well as therapies looking to improve the quality of weight loss and patients’ persist…biospace · 5d ago
- Moonwalk reloads with $70M and new RNAi prospects for obesityThe California biotech plans to bring its first drug, enabled by licensing technology from a Chinese drugmaker, into clinical testing for obesity by the end of 2027.biopharma_dive · 2mo ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that